When does the Xarelto (rivaroxaban) patent expire in the USA?
I can’t determine an exact expiration date from the information provided here, because no patent numbers, expiry dates, or source materials were included. Xarelto’s “patent in the USA” question often involves multiple related patents (compound, formulations, methods of use) plus FDA exclusivities, so the relevant date depends on which specific right you mean.
If you share the patent number (or what you’re trying to check—drug compound, a specific formulation, or a specific use), I can help interpret what it covers and how to find its USPTO/Orange Book status.
Which Xarelto patents matter for generic entry in the US?
Generic and biosimilar timelines in the US are usually tied to what’s listed in FDA’s Orange Book for Xarelto and which patents are still enforceable. Xarelto has had multiple patent families listed over time, so “the patent expiry” could mean:
- the end of a listed Orange Book patent term tied to the active ingredient,
- the end of a method-of-use patent,
- the end of exclusivity (which is different from a patent term), or
- a later “last to expire” event after patent term adjustments and litigation stays.
To answer precisely, you need the specific Orange Book listing or the specific patent you’re asking about.
How do you check Xarelto’s patent status in the US (Orange Book / USPTO)?
A typical way to check is to look up:
- The FDA Orange Book listing for Xarelto (rivaroxaban) to see which patents are listed for the specific strength/formulation.
- The USPTO records for those patent numbers to see the legal status and term dates.
If you tell me which Xarelto product (strength and formulation) you mean (for example, tablets vs. other presentations), I can guide you on which Orange Book entries to look for.
Why is “Xarelto patent USA” sometimes confusing?
People often search for “the” Xarelto patent expiry, but the US situation can include:
- multiple overlapping patents in one product listing,
- patent term adjustments that change the nominal term date,
- litigation that can delay generic approval even after a patent term ends, and
- FDA exclusivities that are not the same as patent expiration.
Can generics come out before every Xarelto patent expires?
In many cases, a generic applicant can seek approval before all related patents are gone, but whether it can be marketed depends on the outcome of patent certifications and potential “stay” or “trigger” events tied to the Orange Book patents. The exact answer depends on the certification pathway and the specific patents still listed as applicable.
What would you like to know exactly?
Reply with any one of these and I’ll narrow it to the exact dates/events:
- a specific patent number for Xarelto,
- the Xarelto strength/formulation (e.g., tablet strength),
- whether you want “patent expiry,” “Orange Book last patent,” or “FDA exclusivity,”
- the generic name you’re comparing against (if any).